HIPK2基因变异对肺癌放疗患者重度放射性肺炎风险的影响
本研究为前瞻性观察性研究,纳入169例接受放疗的肺癌患者,采用Sanger测序法进行基因分型,评估HIPK2基因变异与放射性肺炎风险的关系。多因素Cox分析显示,MLD≥15Gy、肺V20≥24%及HIPK2 rs2030712 CC基因型均与≥2级放射性肺炎风险升高显著相关。
要点
- MLD≥15Gy与≥2级放射性肺炎风险升高相关(HR=1.888)。
- 肺V20≥24%与≥2级放射性肺炎风险升高相关(HR=2.126)。
- HIPK2 rs2030712 CC基因型与≥2级放射性肺炎风险升高相关(HR=2.146)。
核心结论
- HIPK2 rs2030712 CC基因型与≥2级放射性肺炎显著相关,可能作为放疗前预测重度放射性肺炎的指标之一,但需更大样本验证。
研究设计与样本
- 前瞻性观察性研究,纳入169例接受放疗的肺癌患者,采用Sanger测序法进行基因分型,注册号NCT02490319。
主要发现
- MLD≥15Gy患者≥2级放射性肺炎风险高于对照(HR=1.888,95%CI:1.186-3.004,P=0.007)。
- 肺V20≥24%患者≥2级放射性肺炎风险高于对照(HR=2.126,95%CI:1.338-3.378,P=0.001)。
- HIPK2 rs2030712 CC基因型与≥2级放射性肺炎发生增加强相关(HR=2.146,95%CI:1.215-3.791,P=0.009)。
关键数值与推荐
- MLD≥15Gy:≥2级放射性肺炎风险HR=1.888(95%CI:1.186-3.004,P=0.007)。
- 肺V20≥24%:≥2级放射性肺炎风险HR=2.126(95%CI:1.338-3.378,P=0.001)。
- HIPK2 rs2030712 CC基因型:≥2级放射性肺炎风险HR=2.146(95%CI:1.215-3.791,P=0.009)。
临床怎么用
- 放疗前可考虑检测HIPK2 rs2030712基因型,结合MLD和肺V20等剂量学参数综合评估≥2级放射性肺炎风险。
局限性
- 结论需在更大 population 中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Homeodomain-interacting protein kinase 2 (HIPK2) has increasingly drawn attention as recent researches demonstrated its unique role in the regulation of multiple fundamental processes such as apoptosis, proliferation and DNA damage repair. Most importantly, HIPK2 was shown to play regulatory role in inflammation and influence the phenotype and activity of fibroblasts. In this study, we aimed to evaluate the impact of HIPK2 gene variant on risk of radiation pneumonitis for patients with pulmonary malignancies. METHODS: 169 lung cancer patients with radiotherapy were included in our prospective study and genotyped by Sanger Sequence method. Multivariable Cox hazard analysis and multiple testing were applied to estimate the hazard ratio (HR) and 95% confidence intervals (CIs) of all factors possibly related to the risk of radiation pneumonitis (RP). RESULTS: Patients with Mean Lung Dose (MLD) ≥ 15Gy, Lung V20 ≥ 24% had higher risk of RP ≥ grade 2 compared with those counterparts (HR = 1.888, 95% CI: 1.186-3.004, P = 0.007; HR = 2.126, 95% CI: 1.338-3.378, P = 0.001, respectively). Importantly, CC genotype of HIPK2: rs2030712 were strongly related to an increased occurrence of RP ≥ grade 2 (HR = 2.146, 95% CI: 1.215-3.791, P = 0.009). CONCLUSION: HIPK2: rs2030712 was found to be significantly related to RP of grade ≥ 2 in our cohort, and may thus be one of the important predictors of severe RP before radiotherapy, if further validated in larger population. TRIAL REGISTRATION: Our study was prospective and observational. The research was registered in ClinicalTrials.gov database as NCT02490319.
引用
- Tang Y, Yang L, Qin W, et al. Impact of genetic variant of HIPK2 on the risk of severe radiation pneumonitis in lung cancer patients treated with radiation therapy. Radiat Oncol. 2020. PMID: 31915028. doi:10.1186/s13014-019-1456-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。